Tracleer Bosentan Tablets
Home | Site Map | Glossary | Privacy Policy | Terms of Use | Contact Us  

For patients with pulmonary arterial hypertension (PAH, WHO Group I)
WHO Class II, III, IV


Monitor and manage

  Monthly pregnancy and liver-function monitoring is mandatory.1
  Manage LFT elevations if they occur.1
  No change of monitoring or dosage is needed for liver function tests (LFTs) ≤3 × upper limit of normal (ULN).1
  98% maintained treatment with Tracleer without discontinuations due to LFT elevations.2
— Discontinuation rate in Tracleer clinical trials was 3% placebo vs 6% Tracleer.1
Tracleer can be reintroduced if LFTs return to pretreatment levels.1
— Tracleer should not be reintroduced for LFTs >8 × ULN.
— Aminotransferase levels should be checked within 3 days and thereafter according to the recommendations in Warnings and Precautions.

Tracleer aminotransferase (ALT/AST) management1
ALT/AST levelTreatment and monitoring recommendations
1 to 3 × ULNContinue to monitor; no change in monitoring schedule or dosage
>3 to ≤5 × ULNConfirm by another test; if confirmed, reduce the dose or interrupt treatment and monitor LFT levels every 2 weeks

Continue or reintroduce Tracleer if levels return to pretreatment levels
>5 to ≤8 × ULNConfirm by another test; if confirmed, stop therapy; monitor LFTs at least every 2 weeks

Consider reintroduction of therapy if LFTs return to pretreatment levels
>8 × ULNStop therapy; do not reintroduce

If Tracleer is reintroduced, it should be at the starting dose; aminotransferase levels should be checked within 3 days and thereafter according to the recommendations above.

If liver aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥2 × ULN, treatment should be stopped. There is no experience with the reintroduction of Tracleer in these circumstances.

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset liver injury in WHO Class II patients, which may preclude future use as their disease progresses.

Important safety information

Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program.

Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring)—Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter.

High potential for major birth defects—Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.

Contraindicated for use with cyclosporine A and glyburide.

Please see full prescribing information including BOXED WARNING.




  1. Tracleer (bosentan) full prescribing information. Actelion Pharmaceuticals US, Inc. August 2009.
  2. Data on file, Actelion Pharmaceuticals.
x
You are now attempting to email another party outside of Tracleer.com. All emails are between you and that party. See Terms of Use.

Click here to leave Tracleer.com.
x
You are now leaving the Tracleer.com website to go to sitename.

Click here to continue.
You are being redirected to sitename.